Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.

[1]  M. Humbert,et al.  Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.

[2]  T. Fleming,et al.  Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. , 2011, Chest.

[3]  G. Simonneau,et al.  Perspective on the optimal endpoints for pulmonary arterial hypertension trials , 2010, Current opinion in pulmonary medicine.

[4]  H. Ghofrani,et al.  Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[5]  G. Simonneau,et al.  The use of combination therapy in pulmonary arterial hypertension: new developments , 2009, European Respiratory Review.

[6]  P. Thistlethwaite,et al.  Development and pathology of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[7]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[8]  A. Branzi,et al.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[9]  M. Humbert,et al.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. , 2006, European heart journal.

[10]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[11]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.